Laura Stone

Ms. Laura Stone

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
LSLaura Stone
Laura Stone
CSCory Swingen
Cory Swingen
CHChristopher Holley
Christopher Holley
CWChristin Wright
Christin Wright
ECErin Chappuis
Erin Chappuis
RKRosemary F. Kelly
Rosemary F. Kelly

1 July 2021 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
LSLaura Stone
Laura Stone
CSCory Swingen
Cory Swingen
CWChristin Wright
Christin Wright
SQSteven S. Qi
Steven S. Qi
MRMatt Rassette
Matt Rassette
RKRosemary F. Kelly
Rosemary F. Kelly

30 December 2019 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
LSLaura Stone
Laura Stone
ECErin Chappuis
Erin Chappuis
CWChristin Wright
Christin Wright
RKRosemary F. Kelly
Rosemary F. Kelly
EMedward mcfalls
edward mcfalls
Background: Expression of mitochondrial proteins is reduced within hibernating myocardium (HM). It is unclear whether dietary supplementation with CoQ10 can increase expression of mitochondrial electron transport chain (ETC) and antioxidant proteins within this tissue. In a swine model of HM, we tested whether dietary administration of CoQ10 for four weeks enhances the expression of ETC and antioxidant proteins within the mitochondria via increased PGC1α signaling. Methods: 12 swine were instrumented with a fixed constrictor around the LAD artery to induce gradual stenosis. At three months, transthoracic ECHO was performed to confirm the presence of a wall motion abnormality in the anterior wall. Animals were then randomly assigned to receive daily dietary supplements of either CoQ10 (10 mg/kg/day) or placebo for four weeks. At this time, animals underwent a final ECHO and terminal procedure. Expression of nuclear-bound PGC1α (Western blots) and mitochondrial proteins (Tandem Mass Tag) were determined. Results: Mitochondrial and nuclear membranes were isolated from the LAD region. Nuclear-bound PGC1α levels were > 200-fold higher with administration of four weeks of CoQ10 treatment (p = 0.016). Expression of ETC proteins was increased in those animals that received CoQ10. Compared with mitochondria in the LAD region from placebo-treated pigs, CoQ10-treated pigs had higher levels of Complex I (p = 0.03), Complex IV (p = 0.04) and Complex V (p = 0.028) peptides. Conclusions: Four weeks of dietary CoQ10 in HM pigs enhances active, nuclear-bound PGC1α and increases the expression of ETC proteins within mitochondria of HM tissue.

5 January 2024 in Science Advances
Verified
Journal Article
Open access
SJScott Hunter Oppler Jr
Scott Hunter Oppler Jr
LSLaura Stone
Laura Stone
DLDavid John Leishman
David John Leishman
JJJody L. Janecek
Jody L. Janecek
MMMeghan E. G. Moore
Meghan E. G. Moore
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
Cell-based therapies hold promise for many chronic conditions; however, the continued need for immunosuppression along with challenges in replacing cells to improve durability or retrieving cells for safety are major obstacles. We subcutaneously implanted a device engineered to exploit the innate transcapillary hydrostatic and colloid osmotic pressure generating ultrafiltrate to mimic interstitium. Long-term stable accumulation of ultrafiltrate was achieved in both rodents and nonhuman primates (NHPs) that was chemically similar to serum and achieved capillary blood oxygen concentration. The majority of adult pig islet grafts transplanted in non-immunosuppressed NHPs resulted in xenograft survival >100 days. Stable cytokine levels, normal neutrophil to lymphocyte ratio, and a lack of immune cell infiltration demonstrated successful immunoprotection and averted typical systemic changes related to xenograft transplant, especially inflammation. This approach eliminates the need for immunosuppression and permits percutaneous access for loading, reloading, biopsy, and recovery to de-risk the use of “unlimited” xenogeneic cell sources to realize widespread clinical translation of cell-based therapies.

1 January 2019 in Cell Medicine
Verified
Journal Article
Open access
PDF file
LSLaura Stone
Laura Stone
ECErin Chappuis
Erin Chappuis
MMMaribel Marquez
Maribel Marquez
EMEdward O McFalls
Edward O McFalls
RKRosemary F. Kelly
Rosemary F. Kelly
TBTammy Butterick
Tammy Butterick
Hibernating myocardium is a subset of ischemic cardiac disease characterized by viable but dysfunctional tissue. Standard treatment for hibernating myocardium is coronary artery bypass graft, which reduces arrhythmias and improves survival but does not fully restore function, presenting a gap in currently available treatments. Large animal studies of hibernating myocardium have identified impaired mitochondrial dynamics as a root cause of persistent cardiac dysfunction despite surgical revascularization. This study presents a novel in vitro model of hibernating myocardium cardiomyocytes to study active mitochondrial respiration in hibernating myocardium cells, and to test the paracrine effect of mesenchymal stem cells on impaired mitochondrial function. Exposure of cardiomyocytes to hypoxic conditions of 1% oxygen for 24 hours resulted in a phenotype consistent with hibernating myocardium cardiac tissue, including decreased respiratory capacity under high work states, decreased expression of mitochondrial proteins, and preserved cellular viability. Co-culture of hibernating myocardium cardiomyocytes with mesenchymal stem cells restored mitochondrial respiratory function, potentially via an increase in proliferator-activated receptor gamma coactivator 1-alpha-driven mitochondrial biogenesis. Co-culture treatment of hibernating myocardium cardiomyocytes with mesenchymal stem cells shows improvement in both mitochondrial function and ATP production, both of which are critical for effectively functioning cardiac tissue. These results suggest that mesenchymal stem cell therapy as an adjunct treatment to revascularization may address the current gap in treatment for hibernating myocardium patients.

13 April 2023 in Cells
Verified
Journal Article
Open access
PDF file
JBJune Baik
June Baik
COCarolina Ortiz-Cordero
Carolina Ortiz-Cordero
AMAlessandro Magli
Alessandro Magli
KAKarim Azzag
Karim Azzag
SCSarah B. Crist
Sarah B. Crist
RPRita Perlingeiro
Rita Perlingeiro
Pluripotent stem (PS) cells enable the scalable production of tissue-specific derivatives with therapeutic potential for various clinical applications, including muscular dystrophies. Given the similarity to human counterparts, the non-human primate (NHP) is an ideal preclinical model to evaluate several questions, including delivery, biodistribution, and immune response. While the generation of human-induced PS (iPS)-cell-derived myogenic progenitors is well established, there have been no data for NHP counterparts, probably due to the lack of an efficient system to differentiate NHP iPS cells towards the skeletal muscle lineage. Here, we report the generation of three independent Macaca fascicularis iPS cell lines and their myogenic differentiation using PAX7 conditional expression. The whole-transcriptome analysis confirmed the successful sequential induction of mesoderm, paraxial mesoderm, and myogenic lineages. NHP myogenic progenitors efficiently gave rise to myotubes under appropriate in vitro differentiation conditions and engrafted in vivo into the TA muscles of NSG and FKRP-NSG mice. Lastly, we explored the preclinical potential of these NHP myogenic progenitors in a single wild-type NHP recipient, demonstrating engraftment and characterizing the interaction with the host immune response. These studies establish an NHP model system through which iPS-cell-derived myogenic progenitors can be studied.